ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations related to the Company’s technology portfolio to be made at the American Association for Cancer Research (AACR) annual meeting being held April 16-20, 2016 in New Orleans, LA.

ImmunoGen is a recognized leader in the ADC field and invests in new technologies to further extend the types of cancers potentially treatable with this therapeutic approach. Presentations at AACR relate to:

  • Cancer-killing agent/linker innovations – ImmunoGen and partner ADCs in the clinic today all utilize one of the Company’s tubulin-acting maytansinoid agents attached to an antibody using an engineered ImmunoGen linker. The Company has developed a new class of cancer-killing agents – DNA-alkylating IGNs – and multiple purpose-driven linkers and will report new IGN/linker data (abstract #2959).
  • Site-specific attachment innovations – Preclinical studies suggest advantages to site-specific attachment of IGNs, and the Company will have several presentations about site-specific technology innovations (abstracts #2960, #2965, and #2967).
  • Partner program preclinical research – In addition to ImmunoGen’s product programs, nine healthcare companies have licensed rights to utilize Company technology to develop ADCs for specific targets. Two partners will report preclinical ADC data (abstracts #872, #1197, #1198, and #2974).

Additional information – including presentation schedule, titles and full abstracts – can be found at www.aacr.org

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in Phase 2 testing for the treatment of folate receptor α-positive ovarian cancer. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to new technologies. A review of these risks can be found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 and other reports filed with the Securities and Exchange Commission.